

## Anti-CD3e [C3e/1931]

| Catalog No. | Description   |
|-------------|---|
| AM931-5M    | 6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system                                   |
| AM931-10M   | 10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive™ Detection Systems and i6000™ Automated Staining Systems |
| MU931-UC    | 1 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system                                   |
| MU931-5UC   | 0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system                                 |
| AX931-YCD   | Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 160 tests   |
| AX931-50D   | Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 50 tests  |

| Clone    | Species | Ig Class |
|----------|---------|----------|
| C3e/1931 | Mouse   | IgG1     |

### Intended Use

**For Research Use.** This antibody is designed for the specific localization of CD3E in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

### Summary and Explanation

CD3e is part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. The CD3-epsilon polypeptide, which together with CD3-gamma, -delta and -zeta, and the T-cell receptor alpha/beta and gamma/delta heterodimers, forms the T-cell receptor- CD3 complex. The CD3 antigen is first detectable in early thymocytes and probably represents one of the earliest signs of commitment to the T cell lineage. In cortical thymocytes, CD3 is predominantly intra-cytoplasmic. However, in medullary thymocytes, it appears on the T cell surface. CD3 antigen is a highly specific marker for T cells, and is present in majority of T cell neoplasms.

### Storage and Handling

**Store at 2-8°C.** Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

### Principles of the Procedure

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The [primary antibody](#) may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

### Reagents Provided

Mouse Monoclonal Antibody CD3e is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

### Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

### Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

| Parameter  | BioGenex Recommendations  |
|--|---|
| Control Tissue   | Lymph node and tonsil tissue  |
| Recommended Dilution for Concentrated Antibody         | 1:50-100 in HK941   |
| Recommended Pretreatment (Manual/i6000)**              | EZ-AR1 (HK521-XAK)  |
| Recommended Pretreatment (Xmatrx)                      | EZ-AR1 Elegance (HX031-YCD)   |
| Antibody Incubation (Manual/i6000)                     | 30 -60 min at RT  |
| Antibody Incubation (Xmatrx)                           | 30 -60 min at RT  |
| Detection System for Manual, Xmatrx & i6000 systems*** | Use BioGenex Two-Step <b>OR</b> One-Step Super Sensitive™ Polymer-HRP IHC Detection System/DAB; see p. 2 for more information |

\*FB: positive control barrier slides, FG: positive control non-barrier slides. Xmatrx requires barrier slides.

\*\*Pretreatment times will vary based on individual microwave power.

\*\*\*For automation systems (Xmatrx-Elite, Xmatrx-Ultra & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

|              |             |              |              |
|--------------|-------------|--------------|--------------|
| Category     | Antibodies  | Revision No. | E            |
| Document No. | 932-931M-EN | Release Date | JUNE 1, 2021 |

| Detection System   | Two-Step HRP Kit          | One-Step HRP Kit          | Link and Label Kit        |
|--|---------------------------|---------------------------|---------------------------|
| Manual   | QD440-XAKE<br>(1000 Test) | QD630-XAKE<br>(1000 Test) | QP300-XAKE<br>(1000 Test) |
|  | QD430-XAKE<br>(1000 Test) |                           |                           |
|  | QD420-YIKE<br>(500 Test)  | QD620-XAKE<br>(500 Test)  | QP900-9LE<br>(500 Test)   |
|  | QD400-60KE<br>(60 Test)   |                           |                           |
| Xmatrix -<br>Automation  | QD550-YCDE<br>(200 Test)  | QD610-YADE<br>(200 Test)  | N/A                       |
| i6000 -<br>Automation  | QD410-YAXE<br>(200 Test)  | QD610-YAXE<br>(200 Test)  | N/A                       |
| For more information, visit <a href="http://www.biogenex.com">www.biogenex.com</a> . |                           |                           |                           |

### Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

### Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

### Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or [support@biogenex.com](mailto:support@biogenex.com) or your local distributor to report unusual staining.

### Expected Results







This antibody stains cell membrane in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established diagnostic product or procedure.

### Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

### Bibliography

- Mason DY et. al. Detection of T cells in paraffin wax embedded tissue using antibodies against a peptide sequence from the CD3 antigen. J. Clin Path, 1989, 42(11):1194-200.
- Cibull ML et. al. The expression of the CD3 antigen in Hodgkin's disease. Histopathology, 1989, 15(6):599-605.
- Rush J et. al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat biotechnol. 2005, 23(1):94-101
- Brill LM et. al. Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry. Anal Chem. 2004, 15;76(10):2763-72

|  |                        |   |                            |
|--|------------------------|---|----------------------------|
|  | Temperature Limitation |  | Manufacturer               |
|  | Use By Date            |  | Batch Code                 |
|  | Non-Sterile            |  | Consult Instructions for U |

|              |             |              |              |
|--------------|-------------|--------------|--------------|
| Category     | Antibodies  | Revision No. | E            |
| Document No. | 932-931M-EN | Release Date | JUNE 1, 2021 |